RAPP
Rapport Therapeutics
$25.33
−$0.60 (−2.31%)Oct 26, 2026
Key metrics
The numbers that frame RAPP today
- Market cap
- $1.22B
- Gross margin
- 100%
- EV / Sales
- 58.1
- ROIC
- -36%
- Div yield
- 0%
- Debt / equity
- 0.0
- 52wk Low
- $23.75
- 52wk High
- $52.93
Growth
Revenue and earnings trend for RAPP
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about RAPP
Is Rapport Therapeutics a good buy?
No. Rapport Therapeutics has strong momentum, but poor quality undercuts the setup. Growth looks poor. That could put pressure on the long-term business case. We think Rapport Therapeutics is selling at a very high price.
What is the market capitalization of RAPP?
Rapport Therapeutics's market capitalization is $1.22B.
What is the 52-week high for RAPP stock?
The 52-week high for Rapport Therapeutics is $52.93. The current close of $25.33 is 52.1% below that high.
What is the 52-week low for RAPP stock?
The 52-week low for Rapport Therapeutics is $23.75. The current close of $25.33 is 6.7% above that low.
Does RAPP stock pay dividends?
Rapport Therapeutics does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for RAPP?
Rapport Therapeutics's Debt / Equity ratio is 0.02.